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Abstract
There are few predictive biomarkers for antiangiogenic trials in lung cancer. We
examine a potential treatment strategy in which a patient group is enriched
using both histology and an early assessment of response during standard
chemotherapy, and where a new agent is given for the remainder of chemo-
therapy and as maintenance. We performed a retrospective analysis of 722 stage
IIIB/IV non-small-cell lung cancer patients from a double-blind placebo-
controlled trial of thalidomide or placebo 100–200 mg/day, combined with
gemcitabine/carboplatin (for up to four cycles), then given as single agent
maintenance therapy. There was a significant statistical interaction between
treatment and histology, with a possible benefit among squamous cell cancer
(SCC) patients. We examined 150 SCC patients who were “nonprogressors”
(stable disease or complete/partial response) after completing the second chemo-
therapy cycle. Endpoints were progression-free survival (PFS) and overall sur-
vival (OS). Among the 150 patients nonprogressors after cycle 2 (thalidomide,
n = 72; placebo, n = 78; baseline characteristics were similar), the hazard ratios
(HRs) were: OS = 0.76 (95% CI: 0.54–1.07) and PFS = 0.69 (95% CI: 0.50–
0.97). In 57 patients who had a complete/partial response, the HRs were:
OS = 0.63 (95% CI: 0.34–1.15) and PFS = 0.50 (95% CI: 0.28–0.88). SCC
patients who were nonprogressors after 2 cycles of standard chemotherapy
showed evidence of a benefit from thalidomide when taken for the remainder
of chemotherapy and as maintenance. This strategy based on histology and,
importantly, early assessment of tumor response, as a means of patient enrich-
ment, could be examined in other lung cancer studies. Such an approach might
be suitable for trials where there are no predictive biomarkers.
Introduction
Lung cancer remains difficult to treat, largely because
most patients present with advanced disease that is not
amenable to surgery or radical radiotherapy. Currently,
patients with advanced non-small-cell lung cancer
(NSCLC) are frequently selected for treatment based on
their tumor histology. In the first-line JMDB trial, sur-
vival was significantly improved among patients with
nonsquamous histology who received cisplatin/pemetr-
exed, while cisplatin/gemcitabine was more effective for
those with squamous cell cancer (SCC) [1]. Similarly, in
the JMEN study of maintenance pemetrexed in advanced
NSCLC patients, overall survival (OS) and progression-
free survival (PFS) were only improved in nonsquamous
patients [2].
In 2009, we reported the results of a large randomized
trial of thalidomide (Study 14), an oral antiangiogenic
agent, when combined with first-line gemcitabine/car-
boplatin in advanced stage IIIB/IV NSCLC. There was no
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overall benefit (hazard ratio [HR] = 1.13, 95% confidence
interval [CI]: 0.97–1.32) [3]. However, there was evidence
of a differential treatment effect according to histological
subtype, and the interaction between histology and
thalidomide/placebo was statistically significant (P =
0.006). Among patients with SCC, the 2-year survival
rates were 20% (thalidomide) versus 12% (placebo): a
difference of +8% (95% CI: 1 to +17; P = 0.10). The
OS Kaplan–Meier treatment curves for squamous patients
appeared to overlap early, after which they separated. We
believe that the overlap early on could be due to includ-
ing patients who are unlikely to benefit from chemother-
apy, but patients with a tumor response or stable disease
might have more opportunity to benefit from an agent
like thalidomide, when combined with chemotherapy. We
therefore investigated the strategy of using histology and
early tumor response together in selecting patients in
whom new therapies are more likely to show benefits.
Materials and Methods
We conducted a further analysis of a randomized double-
blind placebo-controlled trial of thalidomide. The study is
registered with ISRCTN (77341241). Full details have
been described elsewhere [3]. Briefly, the trial included
722 patients with histologically or cytologically confirmed
stage IIIB/IV NSCLC (recruited 2003–2005), with no
prior chemotherapy or radiotherapy for their cancer. The
cytotoxic drugs were gemcitabine 1200 mg/m2 given
intravenously (days 1 and 8), and carboplatin area under
the curve 5 or 6, dependent on method of glomerular fil-
tration rate estimation (day 1); and given for up to four
cycles. Patients were randomly allocated to receive thalid-
omide or matching placebo capsules, to be taken orally
once daily from the start of chemotherapy for 2 years.
The starting dose was 100 mg/day during chemotherapy
and, if tolerated, increased to 150 mg/day at the end of
chemotherapy for 1 month, then to 200 mg/day mainte-
nance dose for the rest of the trial.
Assessments were performed at each chemotherapy
cycle, which included physical and neurological examina-
tions, hematology and chemistry, a chest radiograph, and
(usually after cycles 2 and 4) computed tomography scan
of the thorax and abdomen. After chemotherapy, the
same assessments were scheduled every 2 months for the
first 2 years, then every 3 months.
Statistical analyses, that is, HRs and Kaplan–Meier
curves, were examined for two endpoints: OS and PFS.
PFS was taken as the date of first recurrence or death. OS
and PFS were measured from the date of the tumor
assessment after cycle 2, or from the date of randomiza-
tion. We examined all patients according to histology and
whether they achieved disease control to treatment by the
end of chemotherapy cycle 2 (i.e., stable disease, or partial
or complete response, referred to as “nonprogressors”).
Tumor response was assessed using the Response Evalua-
tion Criteria in Solid Tumors [4]. Conducting trials sepa-
rately in patients with squamous and nonsquamous
histology is now commonplace, as are maintenance stud-
ies that focus on patients who respond to initial first-line
treatment. The analyses we present here are simply a
combination of these two aspects.
Results
Of the 722 patients randomized, 483 (67%) had nonsqua-
mous histology. The remaining 239 (33%) had tumors of
SCC, of whom 150 patients had at least stable disease at
the end of chemotherapy cycle 2. Among these patients
(n = 150), 93 (62%) had stable disease, 55 (37%) had a
partial response, and 2 (1%) had a complete response.
Baseline characteristics were similar between the thalid-
omide and placebo groups among the 150 SCC patients
who were nonprogressors, that is, had at least stable dis-
ease (Table 1), including tumor response.
Table 2 shows the results on OS and PFS. There was
some evidence of a benefit for both outcomes among all
239 SCC patients (HRs of 0.84 for each endpoint). The
effect was greater when focusing only on the n = 150
Table 1. Baseline characteristics among patients with squamous
histology only who had at least stable disease at the end of chemo-
therapy cycle 2.
Thalidomide
(N = 72),
n (%)
Placebo
(N = 78),
n (%)
P-value for
difference
between
treatment
groups
Age at randomization (years)
50 68 (94.4) 76 (97.4) 0.35
Median 63 66
Range 36–77 48–83
Sex
Male 55 (76.4) 59 (75.6) 0.91
Female 17 (23.6) 19 (24.4)
ECOG performance status
0 24 (33.3) 24 (30.8) 0.82
1 39 (54.2) 46 (59.0)
2 9 (12.5) 8 (10.3)
Stage
IIIb 44 (61.1) 48 (61.5) 0.96
IV 28 (38.9) 30 (38.5)
With pleural effusion (IIIb) 8 of 44 18 of 48
Tumor response at the end of cycle 2
Complete response 2 (2.8) 0 0.34
Partial response 23 (31.9) 32 (41.0)
Stable disease 47 (65.3) 46 (59.0)
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nonprogressors after cycle 2; the PFS HR = 0.71 (95% CI:
0.51–0.99, P = 0.04). Figure 1 is the Kaplan–Meier curves
for PFS. After adjustment for the baseline characteristics
(age, sex, performance status, tumor stage, and presence
of pleural effusion), the HR = 0.69 (95% CI: 0.49–0.98,
P = 0.037). When OS and PFS were measured from the
tumor assessment date following cycle 2, the results were:
PFS HR = 0.69 (95% CI: 0.50–0.97, P = 0.03) and OS
HR = 0.76 (95% CI: 0.54–1.07, P = 0.12). These became
0.67 (95% CI: 0.48–0.95, P = 0.02) and 0.75 (95% CI:
0.53–1.06, P = 0.11), after allowing for the baseline char-
acteristics. The lack of statistical significance for some of
the comparisons in Table 2 is expected because the trial
was not powered for these subgroup analyses.
Thalidomide seemed to be beneficial in all 150 SCC
patients who were nonprogressors, but with a greater
effect among the 57 patients who had a complete/partial
response only (PFS HR = 0.50, 95% CI: 0.28–0.88,
P = 0.02 and OS HR = 0.63, 95% CI: 0.34–1.15,
P = 0.13), than the 93 patients who had stable disease
only (PFS HR = 0.88, 95% CI: 0.58–1.34, P = 0.54 and
OS HR = 0.82, 95% CI: 0.53–1.25, P = 0.35; Fig. 2).
Although the effect in the patients with stable disease was
smaller and not statistically significant, we cannot reliably
rule out a potential benefit, due to the smaller sample size.
There was no benefit associated with thalidomide in
patients with nonsquamous histology. In fact the data
indicated that both OS and PFS were worse in the thalid-
omide group (Table 2).
Among the 150 SCC patients who were nonprogressors
after cycle 2, the percentage with grade 3/4 adverse events
were: 51% (thalidomide) versus 49% (placebo) for hema-
tological toxicities and 32% (thalidomide) versus 23%
(placebo) for nonhematological toxicities, similar to that
found for all trial patients. The main adverse event found
in all patients was thrombotic events, and the HR among
the 150 patients was 1.29 (95% CI: 0.54–3.12), lower than
in all patients (1.74, 95% CI: 1.20–2.52), probably because
these events were more likely to occur earlier on [3].
We examined duration of study drug among the 150
patients who had at least stable disease. Ten patients
Table 2. Summary results for overall survival and progression-free survival according to histology (the hazard ratio is for thalidomide vs. placebo).
OS PFS
Number of
events/Number
of patients HR P-value
Number of
events/Number
of patients HR P-value
All patients 665/772 1.13 (0.97–1.32) 0.12 698/722 1.10 (0.95–1.28) 0.20
Squamous cell lung cancer only 218/239 0.84 (0.64–1.09) 0.19 229/239 0.84 (0.64–1.09) 0.19
Squamous patients who were
nonprogressors1 after two cycles
134/150 0.77 (0.55–1.08) 0.13 143/150 0.71 (0.51–0.99) 0.04
OS and PFS measured from tumor assessment date 0.76 (0.54–1.07) 0.12 0.69 (0.50–0.97) 0.03
Nonsquamous cell lung cancer only 447/483 1.32 (1.10–1.60) 0.004 469/483 1.26 (1.05–1.52) 0.013
Nonsquamous patients who were
nonprogressors1 after two cycles
268/295 1.40 (1.10–1.78) 0.007 286/295 1.31 (1.04–1.66) 0.02
PFS, progression-free survival; OS, overall survival. OS and PFS measured from date of randomization unless otherwise indicated.
1Stable disease, partial, or complete response.
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Figure 1. Progression-free survival (upper) and overall survival (lower)
among 150 patients with squamous histology who had at least stable
disease after chemotherapy cycle 2 (tumor assessment made at the
end of cycle 2).
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(seven placebo and three thalidomide patients) continued
until they died. Among the others, the median time
(25th–75th per centiles) from the date of tumor assess-
ment after cycle 2 until they stopped study drug was 6.1
(2.8–12.1) and 3.8 (1.6–8.5) months in the placebo and
thalidomide groups, respectively. This difference was just
statistically significant (P = 0.04), but consistent with data
from all patients where the drug duration for thalidomide
patients tended to be shorter because of adverse events,
such as thrombotic events.
Only four patients received additional chemotherapy:
placebo (pemetrexed n = 2, docetaxel n = 1) and thalido-
mide (etoposide/cisplatin), and there were only five
patients in each trial group who had a biological agent.
The proportion who received radiotherapy was also simi-
lar: 58% (placebo, 45/78) and 51% (thalidomide, 37/72).
Discussion
Our analyses suggest that histology combined with tumor
response after two cycles of chemotherapy could be used to
identify a group of patients in which some antiangiogenics
might be more effective. In our particular case, these were
patients with SCC who had at least stable disease and trea-
ted with thalidomide. Our study is a post hoc analysis,
which cannot be used to claim effectiveness of thalidomide,
and a prospective study needs to be conducted to confirm
or refute our findings. It is possible that this strategy by
selecting patients who have at least stable disease after cycle
2, as a means of patient enrichment, could lead to a better
prognosis group who are more likely to respond to many
other new antiangiogenics and novel agents without pre-
dictive biomarkers and not just thalidomide.
We used tumor response after chemotherapy cycle 2
because it is routine to perform tumor assessment at this
time, and it also provides a good balance between not
excluding too many patients (63% of squamous patients
would be included on this basis) and a worthwhile treat-
ment benefit (PFS HR = 0.71), that was statistically sig-
nificant (P = 0.04). If stable disease were also excluded,
only 24% of squamous patients would be selected.
Previous trials have used patient or tumor characteris-
tics to preselect patients but only to evaluate a new treat-
ment when given as maintenance (i.e., the assessment of
tumor response is made after chemotherapy finishes). In
others, the new treatment is combined with standard che-
motherapy in all patients at the start of chemotherapy,
and then continues as maintenance monotherapy. The
design we propose here is different from these two
approaches: preselect patients (based on histology and
tumor response), but the assessment of response is made
during chemotherapy. The new treatment is only given to
those with at least stable disease, but is combined with
chemotherapy for the remaining cycles, and then as main-
tenance monotherapy after chemotherapy finishes. The
important feature is the early assessment of tumor
response during standard chemotherapy. This strategy
could be applied to patients with either squamous or
nonsquamous histology. The proposed approach would
be especially useful where patients would not be selected
for treatment on the basis of a validated biomarker (e.g.,
epidermal growth factor receptor [EGFR] mutation). His-
tology and early response could, in fact, be a surrogate of
a predictive biomarker(s) not yet identified.
The JMEN, SATURN, and PARAMOUNT trials are
examples of studies that used tumor response to preselect
a subgroup of patients, but only after they completed all
chemotherapy, and only to investigate maintenance treat-
ment, pemetrexed or erlotinib [2, 5, 6]. In the JMEN
study with maintenance pemetrexed, both OS and PFS
were improved in nonsquamous patients (OS HR = 0.79,
P < 0.012; PFS HR = 0.6, P < 0.0001), but not in squa-
mous patients (OS HR = 1.07, P = 0.68; PFS HR = 1.03,
P = 0.9) [2]. In the SATURN trial maintenance, erlotinib
improved OS (HR = 0.81, P = 0.009) and PFS
(HR = 0.71, P < 0.0001) [5].
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Figure 2. Progression-free survival among 150 patients with
squamous histology, according to type of response after cycle 2 (57
with complete/partial response and 93 with stable disease).
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If future trials adopting the design we propose here
were to confirm the findings, this would have an impor-
tant influence on finding new targeted treatments, espe-
cially where there is no known predictive biomarker. The
results of many studies of angiogenesis and targeted treat-
ments in lung cancer have been disappointing because of
the lack of an effective biomarker to select patients who
can benefit from these agents [7]. Histology and tumor
response, as eligibility criteria, are readily available, with-
out the need for collecting and analyzing blood or tumor
samples, and validating the biomarkers prospectively, a
process which can be expensive, time-consuming, and
delay treatment. Selecting patients on the basis of histol-
ogy and tumor response, instead of biomarkers, could
also allow more patients to be randomized in trials of
new agents because there might be more patients with
these characteristics than those who are biomarker posi-
tive. For example, in the EURTAC study, comparing erl-
otinib with chemotherapy in patients with EGFR
activating mutations, 1227 patients were screened but
only 174 (14%) were eligible [8].
Several studies show that NSCLC patients have different
outcomes according to histology. Patients with non-
squamous tumors have responded better to pemetrexed/
cisplatin than gemcitabine/cisplatin (HR = 0.81, P =
0.005), compared to squamous tumors (HR = 1.23, P =
0.05) [1, 2]. A systematic review of first-line platinum ther-
apy found that cisplatin-based combinations were superior
for third-generation regimens among nonsquamous
patients (HR = 0.89, 95% CI: 0.81–0.99), but with no clear
benefit among squamous patients [9]. Bevacizumab, an
angiogenic inhibitor, is currently licensed to treat patients
with nonsquamous histology only based on the ECOG
4599 trial. This study demonstrated improved median OS
among nonsquamous patients given bevacizumab plus car-
boplatin/paclitaxel compared with chemotherapy alone
(HR = 0.79, P = 0.003) although other studies did not
show survival benefit [10–12]. SCC patients were excluded
from bevacizumab-based trials because of increased life-
threatening and fatal pulmonary hemorrhages seen in a
phase II study, despite a paradoxical observation of signifi-
cant cavitating response seen in squamous tumors [13]. It
has been postulated that the increased risk of severe pul-
monary hemorrhage may be related to the usual central
location and propensity for cavitation but another possi-
bility is a significant “super” response.
Other antiangiogenic studies also do not report benefit
among SCC. A recent phase III study (MONET) investi-
gating the multikinase tyrosine kinase inhibitor motesanib
(AMG 706) plus carboplatin/paclitaxel reported an
increase incidence of hemoptysis in SCC patients [14]. In
the ESCAPE trial, patients with squamous histology
receiving sorafenib plus carboplatin/paclitaxel had an
increased incidence of fatal bleeding events and an unex-
plained increased risk of death (HR = 1.85) [15]. It is not
clear why our SCC patients benefited from thalidomide
but nonsquamous patients had a poorer survival in con-
trast to the above antiangiogenesis trials [10, 15, 16].
Apart from inhibiting tumor angiogenesis by interfering
with fibroblast growth factor (FGF)/fibroblast growth fac-
tor receptor (FGFR) signaling pathway in SCC [17], it is
also possible that thalidomide may inhibit the amplified
or mutated FGFR oncogenic aberrations often seen in
SCC but rarely seen in lung adenocarcinoma [18]. In
SCC, amplification of FGFR1 is seen in up to 20% of
tumors and our trial design may fortuitously further
enrich the FGFR1 positivity rate, thereby allowing thalid-
omide to work [19, 20].
It is of interest whether thalidomide exerts other anti-
tumor effects beside antiangiogenesis, given the lack of
benefit clinical trials using antiangiogenic agents (includ-
ing bevacizumab) for the treatment of SCC. Translational
work on our thalidomide trial, in which we examined
vascular endothelial growth factor (VEGF), soluble
truncated form of VEGF receptor-2 (sVEGFR-2), interleu-
kin-8, tumor necrosis factor-a, basic FGF, and soluble
intercellular adhesion molecule-1 in the plasma did not
show any association with response to thalidomide [21].
Unfortunately, we did not collect paraffin blocks in our
trial to examine FGFR expression or immuno-modulatory
markers in SCC in order to study whether they correlate
with clinical benefit of thalidomide.
Currently, there is an unmet need for first-line trials in
patients with squamous histology. The results from our
thalidomide study presented here on PFS were sufficiently
statistically significant to warrant a prospective study, espe-
cially given that the effect was stronger when focusing only
on those who had a complete or partial tumor response.
We designed a randomized double-blind placebo-
controlled phase II trial of BIBF 1120 (Vargatef TM, Boehrin-
ger Ingelheim GmbH, Ingelheim, Germany), an oral triple
angiokinase inhibitor that inhibits VEGFR-2, platelet-
derived growth factor receptor, and also FGFR, for patients
with squamous histology who have at least stable disease
after two cycles of gemcitabine/cisplatin (LUME-Lung 3),
which is currently ongoing (http://clinicaltrials.gov/ct2/
show/NCT01346540) [22]. BIBF 1120 would then be given
daily from chemotherapy cycles 3 to 6, and as maintenance.
A subgroup analysis would compare the effects between
SCC patients with stable disease and complete/partial
response. We believe that the timing of BIBF 1120 (i.e.,
after two cycles of chemotherapy) is important. This
enriching strategy will exclude patients who are unlikely to
benefit from conventional upfront chemotherapy treat-
ments, and potentially reduce the risks of severe pulmonary
hemorrhage due to central cavitations, given that the risks
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are highest early during treatment. Other studies could
explore the new thalidomide analogs based on our findings.
In routine practice, patients are often staged with imag-
ing after two cycles and further chemotherapy is not
given to nonresponding patients. Our design of introduc-
ing a biological agent only for stable or responding
patients after two cycles will therefore complement the
current clinical algorithm. In the case of antiangiogenic
treatment trials, it also allows exploitation of its tumor
vasculature and intratumoral pressure normalizing prop-
erties, which can further improve cytotoxic drug delivery
for the remaining chemotherapy treatments. This strategy
of “enriching” the patient population for additional treat-
ments may also maximize the chance of finding a more
successful drug combination and boosting biological trials
(where a biomarker has yet to be identified), including
those targeting squamous tumors.
In conclusion, our findings suggest that SCC patients
who responded or had stable disease after two cycles had
improved PFS and OS when thalidomide was given during
the remaining chemotherapy cycles and as maintenance. A
prospective randomized phase II study is underway to
confirm or refute this approach, using a different antiangi-
ogenic agent with FGFR inhibiting property, to investigate
the possibility that this is an effective strategy for selecting
patients likely to benefit from some novel agents. This
enriching strategy should also be investigated in other
studies using different antiangiogenic agents and other
classes of drugs with no validated biomarkers. We also
suggest that researchers of ongoing trials should examine
their data in relation to both histology (either nonsqua-
mous or squamous) and early assessment of tumor
response, as prespecified subgroup analyses.
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